Applied Therapeutics Inc

NASDAQ:APLT  
23.32
+0.85 (+3.78%)
Regulatory, Other Pre-Announcement

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Published: 11/12/2020 12:18 GMT
Applied Therapeutics Inc (APLT) - Applied Therapeutics Reports Third Quarter 2020 Financial Results.
Q3 Loss per Share $1.33.
Q3 Earnings per Share Estimate $-1.02 -- Refinitiv Ibes Data (analyst estimates).
On Track to Initiate Rare Disease Franchise Expansion Programs in Sord Deficiency & Pmm2-cdg Studies in H1 of 2021.
Continued Collaboration With FDA to Restart Action-galactosemia Kids Pediatric Study in Quarter.
Continued Enrollment in Arise-hf Phase 3 Global Registrational Study of At-001 in Diabetic Cardiomyopathy in Quarter.
Plans to Submit an NDA for Pediatric Galactosemia Clinical Study No Later Than Q3 2021.
As of Sept 30, 2020, Cash, Cash Equivalents & Short-term Investments Totaled $116.5 Million Versus $38.9 Million at Dec 31, 2019.